New Psychedelic Research Nonprofit Teams with Johns Hopkins University for Real-World Study on Use of Psilocybin MushrooPharmaDrug Inc. Enters into Definitive Agreement to Acquire First Smart Shop in the NetherlandsCybin Corp. Is A Multi-Faceted Life Sciences Company Investors Should Have On Their RadarMindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic WellneNovamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.Psychedelic Assisted Therapy Is Becoming A Very Real Alternative Method To Treat Mental IllnessNuminus and Together We Can Partner to Support Addiction Recovery and Mental WellnessMydecine Innovations Group Inc. Appoints Previous Red Bull Sports Marketing Director Jim Gunning as CMOGood2Go Corp. and Magical Brands Inc. Announce Update to Proposed Qualifying TransactionThe Psychedelic Legalization Movement Is In Full BloomNuminus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4.05 MillionNuminus Wellness Is Putting Key Pieces In Place To Drive Cutting Edge Research In The Field Of PsychedelicsMagicMed Industries Inc. Announces Brokered Private Placement with Mackie Research Capital CorporationCybin Corp. Announces Proposed Management Team and Board of Directors of the Resulting IssuerMydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading EuropeanWill Psychedelics Take The Same Trip Down The Road To Legalization As The Cannabis Industry?PharmaDrug Inc. Proposes a Strategic Mutual Investment with Red Light Holland Corp.Pure Extracts Has Significant Leverage To Both The Cannabis and Psychedelic SectorsRritual Mushrooms Is Here to Enhance You Daily “Ritual”MagicMed Industries Files First Psychedelic Derivative Patent

Technical420 Site Search

Returned 6 result(s).

Mindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic Wellness

Mydecine Innovations Group™ (CSE: MYCO) (OTC: NLBIF) (FSE:0NF) ("Mydecine"), is pleased to announce that its subsidiary, Mindleap Health™ (“Mindleap” or the “Company”) based in Vancouver, British Columbia, is expanding it’s digital therapeutic offerings by adding three additional programs to its platform. Mindleap™ is working towards contributing to the evolution of…

Mydecine Innovations Group Inc. Appoints Previous Red Bull Sports Marketing Director Jim Gunning as CMO

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE: 0NF) ("Mydecine" or the "Company"), is pleased to announce that they have hired former Red Bull marketing executive, Jim Gunning, as the Company's new Chief Marketing Officer ("CMO"). "When I was first contacted by Damon Michaels, the company's Chief Operations Officer,…

Mydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading European Research Institute

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that, further to its press release of July 14, 2020, its prospective acquisition target NeuroPharm Inc. ("NeuroPharm"), a developer of natural health, psychedelic based treatments for PTSD and other serious mental health disorders in…

Mydecine Innovations Group Adds Former Pfizer, Novartis, Yale Drug Discovery Expert to Scientific Advisory Board

Mydecine Innovations Group Inc. (CSE: MYCO) (OTC: MYCOF) (FSE:0NF) ("Mydecine" or the "Company"), is pleased to announce that it has added world renowned drug discovery expert Dr. Denton Hoyer to its Scientific Advisory Board. Dr. Hoyer has been involved in drug discovery at leading pharmaceutical companies and research institutions for the last…

Mydecine Innovations Group Bolsters Scientific Advisory Board Adding a Leading Neuroscientist and a Psychopharmacology Specialist

Mydecine Innovations Group Inc. (CSE:MYCO) (OTC: MYCOF) is pleased to announce the addition of two key strategic advisors to the company's Scientific Advisory Committee. The new members of the science team will provide scientific expertise and corporate strategy support as Mydecine begins its R&D program at its Innovation Center in Denver,…

Mydecine Innovations Group Signs Definitive Agreement to Acquire Mindleap Health’s Advanced Digital Telehealth Platform

Mydecine Innovations Group Inc. (CNSX: MYCO) (OTCMKTS: MYCOF) is pleased to announce that it has signed a definitive share exchange agreement with Mindleap Health Inc. for the acquisition of a 100% interest in MindLeap’s Digital Telehealth Platform focused on the emerging psychedelics industry. Pursuant to the share exchange agreement, Mydecine…

Search Again

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link